Business News/Market/Market Stats/   Natco Pharma Q2 Results

Natco Pharma Q2 Results

BSE: 524816 | NSE: NATCOPHARM | ISIN: INE987B01026 | Sector: Biotechnology & Drugs
790.90 +6.00 (0.76%)Updated : 04 Dec 2023
Fiscal Period2024
Period End DateSep 23
Revenue 1031.40
Total Revenue 1031.40
Costof Revenue Total 215.80
Gross Profit 815.60
Selling/ General/ Admin Expenses Total 122.40
Depreciation/ Amortization 43.60
Other Operating Expenses Total 235.20
Total Operating Expense 617.00
Operating Income 414.40
Interest Inc( Exp) Net- Non- Op Total -42.00
Other Net 29.40
Net Income Before Taxes 439.60
Provisionfor Income Taxes 70.60
Net Income After Taxes 369.00
Minority Interest 0.00
Net Income Before Extra Items 369.00
Net Income 369.00
Income Availableto Com Excl Extra Ord 369.00
Income Availableto Com Incl Extra Ord 369.00
Diluted Net Income 369.00
Diluted Weighted Average Shares 17.91
Diluted EPS Excluding Extra Ord Items 20.60
DPS- Common Stock Primary Issue 1.25
Diluted Normalized EPS 20.60
*All figures in crores except per share values
Recommended For You